Fierce biotech

Welcomed to this year's Fierce Biotech's Fierce 15. Join us in celebrating 2022's best of the best biotech startups. The 20th century was the century of technology.
Trends
Pfizer’s phase 3 gene therapy trial has failed to demonstrate significant improvement in motor function for boys with Duchenne muscular dystrophy (DMD). The …
Fierce Biotech Fundraising Tracker '24: Santa Ana snags $168M; Alzheon adds $100M for Alzheimer's ph. 3. Before taking the reins at Santa Bio, Emtage served …
最新的生物科技新聞、評論和分析,由@FierceBiotech發布。關注我們,了解行業的動態和趨勢。
Fierce Biotech is the dominant B2B news brand for the industry. Our focus daily is on biotech and medtech companies. We cover the drug and device development universe …
Fierce Biotech covers the latest developments and trends in the biotech sector, including mergers, acquisitions, research, and policy. Find out about Biogen's …
Med-Ally, the maker of active medical devices like the VersaStim neuromodulation platform, said it is moving its operations to Goose Creek in Berkeley …
Regulatory tracker: FDA expands label for Regeneron's Kevzara. Here, we're tracking the regulatory progress of in-market products, including expansions into key …
Pfizer’s internal calculation suggests that “on paper” more than eight cancer drugs could become blockbusters, but the New York pharma decided that eight is what it …
NCGS is expanding its business by relocating to a new corporate headquarters, bringing $10 million in investment and creating 80 new jobs, with a …
See more